Insmed (NASDAQ:INSM) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(0.97) by 21.65 percent. This is a 46.48 percent increase over losses of $(1.42) per share from the same period last year. The company reported quarterly sales of $305.964 million which beat the analyst consensus estimate of $303.298 million by 0.88 percent. This is a 229.62 percent increase over sales of $92.823 million the same period last year.